Targets › GPCD3
2 programs from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout May 2041.
Open in Phaseline: the race on GPCD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Zhejiang University | C-CAR031 GPC3-targeting armored CAR-T cell therapy | GPCD3 | Phase 1 | Hepatocellular Carcinoma | May 2041 |
| Zhejiang University | CT0180 Cells humanized anti-GPC3 CAR-T cell therapy | GPCD3 | Phase 1 | Advanced Hepatocellular Carcinoma | – |
Hepatocellular Carcinoma (1) Advanced Hepatocellular Carcinoma (1)
mixed (1), other (1)
Zhejiang University (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.